Details
Stereochemistry | ACHIRAL |
Molecular Formula | C25H28Cl2N4O2.ClH |
Molecular Weight | 523.882 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN(C)C[C@H]1CC[C@@H](CC1)NC2=C(C=NC3=C2N=C(C=C3)C4=CC(Cl)=C(O)C(Cl)=C4)C(C)=O
InChI
InChIKey=XDGWHISAOWEFML-BFLZMHAMSA-N
InChI=1S/C25H28Cl2N4O2.ClH/c1-14(32)18-12-28-22-9-8-21(16-10-19(26)25(33)20(27)11-16)30-24(22)23(18)29-17-6-4-15(5-7-17)13-31(2)3;/h8-12,15,17,33H,4-7,13H2,1-3H3,(H,28,29);1H/t15-,17-;
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C25H28Cl2N4O2 |
Molecular Weight | 487.421 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/27082996
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27082996
OTS-167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which demonstrated antitumor properties in laboratory tests. It is being developed as an anti-cancer drug. The compound has been shown to suppress the growth of breast, lung, pancreatic and prostate cancer cells that express high levels of the MELK protein. OTS167 reached phase II clinical trials in patients with AML, ALL, advanced MDSs, advanced MPNs, or advanced CML and phase I in patients with breast cancer.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q14680|||B7Z6Y0 Gene ID: 9833.0 Gene Symbol: MELK Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24657156 |
0.41 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02768519
In phase I clinical trial on healthy participants OST-167 was given at doses 0.5 mg, 1.0 mg, and 2.0 mg .
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27082996
HeLaM or MCF7 cell lines were treated with 100nM OTS-167 for 2 hours to test the effect of the drug on mitosis.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:18:12 GMT 2023
by
admin
on
Sat Dec 16 11:18:12 GMT 2023
|
Record UNII |
65P731R507
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
71576671
Created by
admin on Sat Dec 16 11:18:12 GMT 2023 , Edited by admin on Sat Dec 16 11:18:12 GMT 2023
|
PRIMARY | |||
|
65P731R507
Created by
admin on Sat Dec 16 11:18:12 GMT 2023 , Edited by admin on Sat Dec 16 11:18:12 GMT 2023
|
PRIMARY | |||
|
OTS-167 MONOHYDROCHLORIDE
Created by
admin on Sat Dec 16 11:18:12 GMT 2023 , Edited by admin on Sat Dec 16 11:18:12 GMT 2023
|
PRIMARY | |||
|
1431698-10-0
Created by
admin on Sat Dec 16 11:18:12 GMT 2023 , Edited by admin on Sat Dec 16 11:18:12 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |